Washington commission issues stop service order against a GLP-1 compounder

Washington's Pharmacy Quality Assurance Commission imposed a stop service order on a GLP-1 sterile compounder, citing sterile compounding and licensure failures, according to a legal analysis of how states regulate compounded GLP-1 drugs and peptides ^[1]. The action targeted a single pharmacy's operations rather than establishing a new statewide rule, and the pharmacy is not named in the analysis ^[1]. When the order was issued and how long it remains in effect have not been reported ^[1].

The order sits on top of a federal framework that has been narrowing. Semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide), were never placed on the FDA's 503A or 503B bulks lists, so compounding them was allowed only through a drug shortage pathway ^[1]. That pathway closed once FDA resolved the tirzepatide and semaglutide shortages ^[1]. Since then, the agency has issued compliance policy guidance on what makes a compounded product "essentially a copy" of an approved drug, proposed excluding these molecules from the 503B bulks list, and sent successive waves of warning letters to compounders and telehealth marketers ^[1].

States cannot go below that federal standard; a state board can add stricter requirements but cannot loosen federal ones ^[1]. Where states differ is enforcement. Ohio's July 2025 guidance says semaglutide and tirzepatide can no longer be compounded as copies after the shortage, prohibits the investigational peptides retatrutide and cagrilintide, and requires active ingredients from an Ohio-licensed distributor, and the state's pharmacy board reports summarily suspending more than thirty clinics and medical spas since the beginning of 2025 ^[1]. California is the one state that has written a substantive standard stricter than federal law, effective October 1, 2025, requiring pharmacists to verify and document a clinically significant, patient-specific reason for a compounded variation and requiring a certificate of analysis that names the active ingredient manufacturer rather than just the distributor ^[1]. Alabama and New Jersey have issued guidance, and Connecticut's attorney general has pursued distributors, med spas and clinics under the state's unfair trade practices law even though its pharmacy regulator has taken no GLP-1 position ^[1]. Texas and Florida are described as representative of most states, which have no GLP-1-specific board position and rely on general compounding rules that already incorporate the federal "essentially a copy" limit ^[1].

The legal form of a state's position matters as much as its content: only California has enacted a GLP-1-relevant rule with the force of law, while the rest is board guidance, newsletters, position statements and consumer alerts that inform enforcement but carry less legal weight ^[1].

Why it matters for patients

Compounded semaglutide and tirzepatide reached many patients through the shortage pathway, and that pathway is closed ^[1]. Federal guidance has also signaled that minor changes, such as adding vitamin B12 alone, are generally not enough to make a compounded product something other than an "essentially a copy" of an approved drug ^[1].

The Washington order shows a second source of pressure: a state board willing to act against a specific pharmacy. A stop service order at one site can cut off refills for people who get compounded products from that pharmacy, though how many patients were affected in this case has not been reported ^[1]. The stated grounds here were sterile compounding and licensure failures, not the choice of molecule, which puts the focus on how and where a product is made rather than only on what it contains ^[1].

The analysis also notes that state boards treat salt forms of a molecule differently from the base form, and that investigational GLP-1s such as retatrutide and cagrilintide are expressly prohibited in some states ^[1]. Marketing is another exposure point: the most active consumer protection and FDA enforcement actions have targeted promotions that suggest a compounded product is FDA-approved or therapeutically equivalent to a brand-name version ^[1].

What happens next

No date has been reported for when the Washington stop service order takes effect or ends ^[1]. FDA has removed twelve peptides from its Category 2 interim bulk substances list and scheduled Pharmacy Compounding Advisory Committee meetings to consider several for the 503A bulks list, with dates not given in the analysis ^[1]. California's rewritten compounding regulations took effect October 1, 2025 ^[1]. The analysis expects enforcement-heavy states like Ohio and Washington to remain higher-risk regardless of where the substantive rule lands, and expects the consumer protection channel to keep policing marketing and sales conduct independently of compounding law ^[1].